Cargando…
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first...
Autores principales: | Addeo, Alfredo, Obeid, Michel, Friedlaender, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246105/ https://www.ncbi.nlm.nih.gov/pubmed/32434788 http://dx.doi.org/10.1136/jitc-2020-000892 |
Ejemplares similares
-
Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023) -
Tracking the tail
por: Friedlaender, Alex, et al.
Publicado: (2020) -
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020) -
Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019) -
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung
Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)